Aggressive breast cancer in western Kenya has early onset, high proliferation, and immune cell infiltration

BMC Cancer

Table 2 Comparison of breast cancer studies from East Africa

Study	Country	City	Patients with Breast Cancer	Retrospective or prospective study design	Female	Male	Ethnic groups considered in study	Immune cells quantified	Median	Mean	ER+	ER-	ER+	ER-	PR+	PR-	PR+	PR-	HER2+	HER2-	HER2+	HER2-	TN	TN	Time Period of Sample Collection	Date of Publication
Study	Country	City	(N)^#	Retrospective or prospective study design	(%)	(%)	Ethnic groups considered in study	Immune cells quantified	age	age	(N)	(N)	(%)	(%)	(N)	(N)	(%)	(%)	(N)	(N)	(%)	(%)	(N)	(%)	Time Period of Sample Collection	Date of Publication
This Study, Sawe et al.	Kenya	Eldoret	48 (68)^A	Prospective	93	7	Yes	CD68, CD163, CD4, CD8, CD20, CD25	48.5	51.9	29	20	59	41	19	29	40	60	7	42	14	86	16	33	2011–2013
Nalwoga et al.	Uganda	Kampala	65^B	Retrospective	100	no ^B	No	None		49.8	23	42	35	65	15	50	23	77	19	46	29	71		34 ^G	1993–2002	2007
Roy et al.	Uganda	Kampala	35 (45)^B,C	Retrospective	96	4 ^C,B	No	None			27	18	60	40					5	39	11	89	16	36	2000–2004	2011
Bird et al.	Kenya	Kijabe	34 (129)^D	Prospective	97	3	No	None	47	48	29		24						9	25	26	74	15	44	2001–2007	2008
Nyagol et al.	Kenya	Nairobi	158^B	Prospective	100	no ^B	No	None		47	59	99	37	63	77	81	49	51	44	114	28	72	44	28	2002–2004	2006
Wata et al.	Kenya	Nairobi	54 (219)^B,E	Retrospective	100	no ^B	No	WBC, platelets	45	46.5	30	34	47	53	28	36	44	56	19	35	35	65			2007–2008	2013
Kantelhardt et al.	Ethiopia	Addis Ababa	352^B	Retrospective	100	no ^B	No	None		40.1-43^H	230	122	65	35	176	168	51	49	n.d.	n.d.	n.d.	n.d.			2005–2010	2014
Burson et al.	Tanzania	Dar es Salaam	57 (488)^I	Retrospective	97	3	No	None		49.4	33	32	51	49	29	36	45	55	n.d.	n.d.	n.d.	n.d.			2009–2010	2010

ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor, TN triple negative (ER-,PR-,HER2-), N number, % = percent, n.d not determined
^#The number before the parentheses is the number of patients used for analysis of receptor status and is summarized individually by the indicated superscripts
The number in parentheses represents the total number of patients with breast cancer in the study.
^A N = 48 patients with PR and triple negative data. N = 49 with ER, HER2 data. Excluded patients who did not provide consent or who had chemotherapy prior to surgery
^BOnly females included in study
^C N = 35 patients with triple negative data. N = 44 patients with HER2 data. 2 of 47 (4 %) patients were male but were excluded from the study
^D N = 34 patients with HER2/triple negative data. 120 patients with hormone receptor data
^E N = 54 patients with HER2 data. N = 64 patients with ER data. N = 64 for PR. Excluded if <18 yrs old, male, or if chart did not have a date of diagnosis
^FNo hormonal receptor data in this study
^GDefined in this study by staining for Cytokeratin 5/6 and P-Cadherin as basal subtype markers, rather than ER, PR, and HER2
^HMean is 43 years old for ER+ and 40.1 years old for ER- patients
^I N = 57 patients with ER and PR data. No HER2 data for these patients

ISSN: 1471-2407